ALK-Positive Lung Non-Small Cell Carcinoma

ALK-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06410040	A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis	unknown	—	28	Sichuan Cancer Hospital and Research InstituteOTHER	1	May 10, 2024	clinicaltrials
NCT05482087	A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC	unknown	Phase 2	190	Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY	1	Aug 1, 2022